Global Solutions For Infectious Diseases
Global Solutions For Infectious Diseases
Want to make a donation using Daffy?
Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.
Do you work for Global Solutions For Infectious Diseases? Learn more here.
By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.
About this organization
Mission
Global Solutions for Infectious Diseases (GSID) aims to expand the development of products for the prevention and diagnosis of infectious diseases afflicting less developed countries. Infectious diseases cause almost half of all deaths in the developing world, whereas they represent less than 5% in the United States. Vaccines are widely seen as the most effective and cost efficient way of managing these public health threats. Diagnostics can ensure proper treatment is prescribed, as well as increase our understanding of the diseases through better surveillance. Despite their potential to dramatically improve global health, developing vaccines and diagnostics for the developing world are not a priority for the private sector, as the financial returns remain minimal. With extensive experience in public health and private sector product development, our team works with biotechnology companies, academic institutions, and other global health organizations to ensure that new products are developed to address those most in need. Together, we all work to find Global Solutions for Infectious Diseases.
About
AIDSVAX HIV Vaccine Program: GSID provided its vaccine product, AIDSVAXB/E, a vaccine designed to prevent infection from HIV-1, to several human clinical trials and non-human studies in Thailand, Switzerland, South Africa, Uganda and the United States. A primary objective of these phase I and II studies is to generate new safety and immunological data which will help design future large-scale efficacy trials planned for the next generation of HIV vaccine candidates and to gain further understanding of why a previously conducted efficacy trial was partially successful. In 2018, GSID entered into a collaboration funded by the European Union to conduct a Phase 2b efficacy trial in four Sub-Saharan countries in Africa. Funding for these activities in 2018 was provided by the Henry M. Jackson Foundation (Bethesda, MD). No activities related to this program were conducted by GSID personnel on the ground in Asia or Sub-Saharan Africa during 2018. GSID established repository containing the serological specimens collected primarily from the first two phase III clinical trials of an HIV/AIDS vaccine. The repository consists of over 30 ultra-low freezer units containing over 300,000 vials of serum and plasma collected from over 8,000 volunteers who participated in the clinical trials. The specimens are provided under material transfer agreements to investigators in the scientific community who are working towards finding a better understanding of the virus that causes AIDS and to those scientists who are developing vaccines to prevent HIV infection. The repository also contains other materials such as: GMP-grade vaccine, manufacturing reagents, research-grade vaccine and data which are also provided to the research community to conduct experiments, pre-clinical trials and human clinical trials; and to develop laboratory assays. In September 2018, the materials repository was relocated to a biopharmaceutical storage facility in Frederick, Maryland.
Interesting data from their 2019 990 filing
The filing specifies the mission of the non-profit as “The specific and primary purpose and charitable mission of global solutions for infectious diseases is to conduct research on and develop vaccines and diagnostics for life-threatening infectious diseases, including hiv. gsid is also committed to provide assistance to and collaborate with other global public health organizations, private foundations, and for-profit entities focused on public health issues, for the purpose of facilitating access to affordable health solutions which benefit the people in developing countries, who are the most in need.”.
When explaining its duties, they were described as: “The mission of gsid is to expand the development of low-cost effective tools for the diagnosis and prevention of infectious diseases afflicting less developed countries.”.
- The state in which the non-profit is authorized to operate legally is CA.
- According to the filing, the address of the non-profit for the year 2019 is 3527 Mt Diablo Blvd 478, Lafayette, CA, 94549.
- The non-profit has reported 5 employees on their form for the year 2019.
- Does not operate a hospital.
- Does not operate a school.
- Does not collect art.
- Does not provide credit counseling.
- Does not have foreign activities.
- Is not a donor-advised fund.
- Is not a private foundation.
- Expenses are greater than $1,000,000.
- Revenue is greater than $1,000,000.
- Revenue less expenses is -$77,167.
- The compensation policy for the CEO of the organization is not based on a thorough evaluation and endorsement by an impartial entity.
- The organization has 1 independent voting members.
- The organization was formed in 2004.
- The organization has a written policy that addresses conflicts of interest.
- The organization is required to file Schedule B.
- The organization is required to file Schedule J.
- The organization is required to file Schedule O.
- The organization pays $985,609 in salary, compensation, and benefits to its employees.
- The organization pays $118,416 in fundraising expenses.
- The organization provides Form 990 to its governing body.
- The organization has minutes of its meetings.